Laboratory Quality Control Market Poised to Hit $2.2 Billion by 2031

Modern clinical laboratories are rapidly moving away from manual, periodic quality checks in favor of continuous, automated monitoring embedded directly into testing systems. Platforms like Roche's navify Lab Operations now facilitate integrated quality management, allowing for automated result suspension when discrepancies arise. This digital evolution is complemented by patient-based real-time monitoring and risk-based approaches, such as the CDC’s Individualized Quality Control Plan, which enables facilities to tailor procedures to their specific testing environments rather than relying on static, one-size-fits-all standards.

Market Drivers and Industry Shifts

The push for standardization is driven by the sheer volume of diagnostic tests performed annually—over 14 billion in the U.S. alone—and the increasing necessity of maintaining regulatory compliance across complex molecular and immunoassay platforms. While North America currently holds the largest market share due to its established infrastructure and rigorous federal standards, the Asia-Pacific region is emerging as the fastest-growing hub. Expansion in China, India, and South Korea is fueled by rapid diagnostic infrastructure growth and the adoption of high-throughput automated systems. However, industry leaders face persistent challenges in standardizing requirements across disparate platforms and managing the implementation costs for smaller, decentralized testing sites. Manufacturers are responding by focusing on sustainability, such as Siemens Healthineers’ recent environmental certifications, and strategic partnerships, including the collaboration between RealBio and Thermo Fisher Scientific to harmonize global standards with local regulatory expertise.